SCHEMBL6797032

SCHEMBL6797032

Cn1c(=O)[nH]c(=O)c2[nH]c([C@@H]3CCC[C@H](NC(=O)OC(C)(C)C)C3)nc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.48
BTK Q06187 1/20 0.43
ADORA2A P29274 3/20 0.42
ADORA2B P29275 3/20 0.42
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39
PMP22 Q01453 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 1/20 0.35
KAT2B Q92831 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL556211 0.86 ADORA2A (0.57) ADORA1BTKADORA2AADORA2BLMNA
SCHEMBL556210 0.86 ADORA2A (0.57) ADORA1BTKADORA2AADORA2BLMNA
SCHEMBL555399 0.86 ADORA2A (0.57) ADORA1BTKADORA2AADORA2BLMNA
SCHEMBL6797026 0.85 ADORA1 (0.46) ADORA1BTKADORA2AADORA2BLMNA
SCHEMBL17130405 0.78 MAP4K4 (0.47) BTK
SCHEMBL25531627 0.72 KMT2A (0.47) BTKSMN1; SMN2KMT2AL3MBTL1
SCHEMBL19014025 0.71 KDM4E (0.44) ADORA1LMNAMAPK1SMN1; SMN2KMT2A
SCHEMBL13719171 0.70 MAP4K4 (0.45) BTKPIM1PIM2
SCHEMBL13719169 0.70 MAP4K4 (0.45) BTKPIM1PIM2
SCHEMBL19013771 0.70 GAA (0.40) ADORA1ADORA2AADORA2BSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077645-A1 Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077645-A1 Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment DPP4, DPP3, DPP7 ADORA1 250/4885BTK 2285/4885ADORA2A 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.